|
|
|
|
LEADER |
01000caa a2200265 4500 |
001 |
OLC1982456639 |
003 |
DE-627 |
005 |
20230513174441.0 |
007 |
tu |
008 |
161013s2016 xx ||||| 00| ||eng c |
024 |
7 |
|
|a 10.1158/1538-7445.AM2016-376
|2 doi
|
028 |
5 |
2 |
|a PQ20161012
|
035 |
|
|
|a (DE-627)OLC1982456639
|
035 |
|
|
|a (DE-599)GBVOLC1982456639
|
035 |
|
|
|a (PRQ)crossref_primary_10_1158_1538_7445_AM2016_3760
|
035 |
|
|
|a (KEY)0108894720160000076001400376abstract376combinationofduvelisibwitheitheribrutin
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
082 |
0 |
4 |
|a 610
|q DNB
|
084 |
|
|
|a XA 10000
|q AVZ
|2 rvk
|
084 |
|
|
|a 44.81
|2 bkl
|
100 |
1 |
|
|a White, Kerry
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Abstract 376: Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines
|
264 |
|
1 |
|c 2016
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
700 |
1 |
|
|a Murphy, Erin
|4 oth
|
700 |
1 |
|
|a Faia, Kerrie
|4 oth
|
700 |
1 |
|
|a Proctor, Jennifer
|4 oth
|
700 |
1 |
|
|a Kosmider, Nicole
|4 oth
|
700 |
1 |
|
|a Pink, Melissa
|4 oth
|
700 |
1 |
|
|a Goldstein, Stanley
|4 oth
|
700 |
1 |
|
|a McGovern, Karen
|4 oth
|
700 |
1 |
|
|a Kutok, Jeffery L
|4 oth
|
773 |
0 |
8 |
|i Enthalten in
|t Cancer research
|d Birmingham, Ala. [u.a.] : AACR, 1941
|g 76(2016), 14 Supplement, Seite 376-376
|w (DE-627)12906775X
|w (DE-600)1432-1
|w (DE-576)014399199
|x 0008-5472
|7 nnns
|
773 |
1 |
8 |
|g volume:76
|g year:2016
|g number:14 Supplement
|g pages:376-376
|
856 |
4 |
1 |
|u http://dx.doi.org/10.1158/1538-7445.AM2016-376
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_OLC
|
912 |
|
|
|a SSG-OLC-PHA
|
912 |
|
|
|a SSG-OLC-DE-84
|
912 |
|
|
|a GBV_ILN_55
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_69
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2219
|
912 |
|
|
|a GBV_ILN_4012
|
912 |
|
|
|a GBV_ILN_4219
|
936 |
r |
v |
|a XA 10000
|
936 |
b |
k |
|a 44.81
|q AVZ
|
951 |
|
|
|a AR
|
952 |
|
|
|d 76
|j 2016
|e 14 Supplement
|h 376-376
|